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Ovarian Cancer G Protein-Coupled Receptor 1, a 
New Metastasis Suppressor Gene in Prostate Cancer
Lisam Shanjukumar Singh, Michael Berk, Rhonda Oates, Zhenwen Zhao, Haiyan Tan, Ying Jiang,
Aimin Zhou, Kashif Kirmani, Rosemary Steinmetz, Daniel Lindner, Yan Xu
Background Metastasis is a process by which tumors spread from primary organs to other sites in the body and is the 
major cause of death for cancer patients. The ovarian cancer G protein-coupled receptor 1 (OGR1) gene has 
been shown to be expressed at lower levels in metastatic compared with primary prostate cancer tissues.
Methods We used an orthotopic mouse metastasis model, in which we injected PC3 metastatic human prostate 
cancer cells stably transfected with empty vector (vector-PC3) or OGR1-expressing vector (OGR1-PC3) into 
the prostate lobes of athymic or NOD/SCID mice (n = 3-8 mice per group). Migration of PC3 cells tran­
siently transfected with vector control or with OGR1- or GPR4 (a G protein-coupled receptor with the 
highest homology to OGR1 (-expressing vectors was measured in vitro by Boyden chamber assays. G pro­
tein alpha-inhibitory subunit 1 (Gαi1) expression after treatment with pertussis toxin (PTX) was measured 
using immunoblotting analysis. The inhibitory factor present in the conditioned medium was extracted 
using organic solvents and analyzed by mass spectrometry.
Results in vivo, all 26 mice carrying tumors that were derived from vector-PC3 cells developed prostate cancer 
metastases (mean = 100%, 95% confidence interval [Cl] = 83.97% to 100%) but few (4 of 32) mice carrying 
tumors derived from OGR1-expressing PC3 cells (mean = 12.50%, 95% Cl = 4.08% to 29.93%) developed 
metastases. However, exogenous OGR1 overexpression had no effect on primary prostate tumor growth 
in vivo. In vitro, expression of OGR1, but not GPR4, inhibited ceil migration (mean percentage of cells 
migrated, 30.2% versus 100%, difference = 69.8%, 95% Cl = 63.0% to 75.9%; P<.001) via increased expres­
sion of Gαi1 and the secretion of a chloroform∕methanol-extractable heat-insensitive factor into the condi­
tioned medium through a PTX-sensitive pathway.
Conclusion OGR1 is a novel metastasis suppressor gene for prostate cancer. OGR1's constitutive activity via Gαi 
contributes to its inhibitory effect on cell migration in vitro.
J Natl Cancer Inst 2007;99:1313-27
Approximately 1.4 million new cancers were diagnosed, and more 
than 564000 deaths from cancer were expected, in the United States 
in 2006 (1). The majority of these cancer-related deaths will be due 
to tumor metastasis rather than to the primary tumors. Thus, the 
major clinical challenge is to combat systemic metastatic disease.
Unlike tumor suppressor genes, such as p53 and Rb, metastasis 
suppressor genes reduce the metastatic propensity of cancer cell 
lines without substantially affecting their tumorigenesis in vivo 
(2-4). Well-defined metastasis suppressor genes include NM23, 
MKK4, KAI1, BRMS1, KiSSl, RHOGDI2, CRSP3, and VDUP1 
(2,5,6). Metastasis suppressor genes operate at different levels in 
the metastatic process (2,3) through mechanisms that involve 
mitogen-activated protein (MAP) kinase (ERK, p38, and JNK 
kinases) regulation, integrin interaction, epidermal growth factor 
desensitization, Gap junction communication, modulation of G 
protein-coupled receptors or G proteins; they can also function as 
coactivators of transcription and inhibitors of thioredoxin (2,3,5). 
Targeting metastasis suppressor genes has high therapeutic poten­
tial. Although there are many steps in metastasis, blocking only
one of these steps may potentially inhibit or prevent metastasis. 
Moreover, unlike classical tumor suppressor genes, most metasta­
sis suppressor genes are not mutated in tumor tissues but instead 
their expression is suppressed by promoter methylation and/or 
other mechanisms. Thus, restoring metastasis suppressor gene ex­
pression may be sufficient to suppress tumor metastasis (5,7).
CONTEXT AND CAVEATS
Prior knowledge
Tumor metastasis is a major cause of death among cancer patients. 
The expression of ovarian cancer G protein-coupled receptor 1 
(OGR1) is higher in primary prostate tumors than metastases.
Study design
Mouse models of prostate cancer metastasis and in vitro migration 
assays using control human prostate cancer cells and those engi­
neered to overexpress OGR1.
Contributions
Cells overexpressing OGR1 formed fewer metastases in the mouse 
models and migrated more slowly in vitro than control cells.
Implications
OGR1 acts as a metastasis suppressor gene in prostate cancer.
Study limitations
Only one prostate cancer cell line was used in the mouse models. 
In these models, this cell line did not metastasize to bone, which is 
one of the most common sites of metastasis in prostate cancer as 
well as other types of cancer. Thus, how OGR1 might affect metas­
tasis to bone is unknown, as is the application of these findings to 
human prostate cancer.
Identifying prostate cancer-related metastasis suppressor genes 
and their mechanisms of action is important for the development 
of novel strategies for the prevention and treatment of metastatic 
prostate tumors. An estimated 234460 new cases and 27 350 deaths 
from prostate cancer were expected in the United States in 2006 
(1). With the introduction of the prostate-specific antigen (PSA) 
screening test, approximately 75% of prostate cancers are detected 
when the disease is clinically confined to the prostate. However, 
in many patients, the cancer often progresses to an androgen- 
independent metastatic stage for which few treatment options are 
available. Several metastasis suppressor genes have been identified 
in prostate cancer, including CD44, NM23, MKK4, and KAI1 (8).
G proteins and G protein-coupled receptors have important 
roles in prostate cancer (9-11) and in other pathologic processes. 
Of the 100 leading pharmaceutical products developed in 2000, 
39 act through a G protein-coupled receptor-mediated mecha­
nism, underlining the importance of G protein-coupled receptors 
as important pharmaceutical targets (12). We have previously 
cloned OGR1, a G protein-coupled receptor from the HEY hu­
man ovarian cancer cell line (13). OGR1 and related subfamily 
members GPR4, G2A, and TDAG8 mediate the functions of 
several lysophospholipids, including sphingosylphosphorylcholine 
(SPC), lysophosphatidylcholine (LPC), and psychosine (14-18), 
which include endothelial barrier function, endothelial cell 
proliferation, migration, and tube formation, T cell migration, gluco­
corticoid-induced thymocyte apoptosis, and globoid cell formation.
In addition, all members of the OGR1 subfamily exhibit proton-
sensing properties (19,20). Using small hairpin RNA to inhibit ex­
pression of GPR4 followed by replenishment with mutant GPR4, we 
have shown that endogenous GPR4 mediates the proliferation, 
migration, and tube formation effects of SPC. In addition, unlike ear­
lier studies in HEK293 cells, for which GPR4 overexpression resulted
in increased cAMP production in response to changes in cellular pH 
(19), we have shown (15) that, in endothelial cells, endogenous GPR4 
does not increase cAMP production in response to pH changes.
Although more extensive work is warranted to further clarify 
these apparently conflicting findings related to pH and lipid regu­
lators and/or modulators, OGR1 and related G protein-coupled 
receptors also possess constitutive activities that do not require 
ligand binding and are not affected by pH changes (15). Many G 
protein-coupled receptors undergo a spontaneous switch between 
their inactive and active states (induced or stabilized by the ago­
nist). When these receptors undergo agonist-independent stabili­
zation of tire active state, tlrey become constitutively active, which 
results in an increase in basal G protein activity. Constitutive activ­
ity is observed in numerous G protein-coupled receptors (21) and 
can be achieved through various mechanisms (12,21-23).
LaTulippe et al. (24) have conducted a comprehensive gene 
expression analysis of prostate cancer using oligonucleotide arrays 
with more than 63 000 probe sets to identify genes and expressed 
sequences with substantial differential expression between non­
recurrent primary prostate cancers and metastatic prostate cancers. 
Interestingly, among the top 100 differentially expressed genes 
that were identified in this study, OGR1 expression was shown to 
be fivefold lower in tumor metastases than primary tumors (24).
In this study, we investigated the role of OGR1 in prostate can­
cer metastasis using an orthotopic model in athymic (nu∕nu) and non- 
obese diabetic/severe combined immunodeficiency (NOD/SCID) 
mice. We also investigated the effects of OGR1 expression on meta­
static prostate cancer cell migration in vitro and the mechanisms 
underlying these effects using stable PC3 prostate cancer cell clones.
Materials and Methods
Materials
Male athymic mice (n = 26, 5-7 weeks old; nu∕nu) were obtained 
from Charles River Laboratories (Wilmington, MA). Male NOD/ 
SCID mice (n = 32, 5-7 weeks old) were obtained either from 
Jackson Laboratory (Bar Harbor, ME) or from Dr Karen Pollok at 
the Indiana University School of Medicine (Indianapolis, IN). Alice 
were housed at the Cleveland Clinic’s Laboratory Animal Resource 
Unit (Cleveland, OH) or at the Laboratory Animal Resource Center 
at the Indiana University School of Medicine. Immunohistochemistry 
kits were obtained from Vector Laboratories (Burlingame, CA). 
G protein alpha-inhibitory subunit (Gαi1) dominant-negative 
cDNAs were purchased from the University of Missouri’s UMR 
cDNA Resource Center (Rolla, MO). Rabbit polyclonal anti-Gαi1 
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). 
Mouse monoclonal anti-BrdU antibody and methylthiazolyldi- 
phenyl-tetrazolium bromide (MTT) were obtained from Sigma 
(St Louis, MO), rabbit polyclonal anti-OGR1 antibody was pur­
chased from LifeSpan BioSciences (Seattle, WA), and rat monoclo­
nal anti-mouse CD49b∕Pan-NK-cells antibody was purchased from 
BD Biosciences (San Jose, CA).
Cell Culture
The androgen-independent metastatic human prostate cancer cell 
line PC3 and the human embryonic kidney 293T (HEK293T) cell
line were purchased from American Type Culture Collection 
(Manassas, VA). The immortalized human microvascular endothelial 
cell line-1 (HMEC-1) was from the Centers for Disease Control and 
Prevention (Atlanta, GA). PC3 and HMEC-1 cells were cultured in 
RPMI-1640. C4-2 and DU145 human prostate cancer cell lines 
(obtained from Dr Warren Heston at the Cleveland Clinic), and 
HEK293T cells were cultured in Dulbecco’s modified Eagle medium. 
Media were supplemented with 10% fetal bovine serum (FBS), 100 
units/mL penicillin-streptomycin, and 2 mM glutamine. Cells were 
maintained in a humidified 5% CO2 atmosphere at 37 oC.
Plasmid Construction
The pcDNA3-OGRl (human) and pcDNA3-GPR4 (human) plas­
mids were generated in our laboratory as described previously 
(12,21-23). OGRl-pMSCV murine stem cell virus retroviral vector 
(MSCV; puromycin) expression plasmids with or without fusion 
to enhanced green fluorescence protein (EGFP) were constructed. 
To construct the pMSCV-3HA-OGRl-EGFP plasmid, the 3HA- 
OGR1-EGFP fragment of the pEGFP-Nl-3HA-OGRl plasmid, 
which we constructed previously (our unpublished results), was 
removed by digestion with NotI and Xhol and was then inserted into 
the pTriEx-1 vector (Novagen, San Diego, CA). Similarly, to con­
struct the pMSCV-3HA-OGRl plasmid, the 3HA-OGR1 frag­
ment was removed from pcDNA3-OGRl by digestion with HindII 
and EcoRI and was then inserted into the pTriEx-1 vector. Both the 
3HA-OGR1 and the 3HA-OGR1-EGFP DNA fragments were 
then excised from the pTriEx-1 vector and inserted into pMSCV 
(puromycin) by digestion with EcoRI and Xhol. The EGFP-coding 
sequence fragment was amplified from the pEGFPNl plasmid (BD 
Biosciences, Palo Alto, CA, GenBank accession code U55762) by 
polymerase chain reaction (PCR) using primers 5'-ACAGTTTAA 
ACTTCGAATTCTGCAGTCGACGG-3'(forward) and 5'-AAT 
GCGGCCGCTTTACTTGTACAGCTCGTCCATGC-3' 
(reverse) and then cloned into pMSCV (puromycin) by EcoRI and 
Xhol digestion. The resulting plasmid pMSCV-EGFP was used as 
the EGFP control vector. An OGR1 mutant, pcDNA3-OGRl- 
H245F was constructed by site-directed mutagenesis. The histidine 
residue of OGR1 at position 245 was replaced with phenylalanine 
using the Quick Change Mutagenesis System (StrataGene Systems 
Inc, La jolla, CA) and tire pcDNA3-OGRl plasmid as the template. 
The mutagenesis was confirmed by sequence analysis.
All plasmid constructs were transformed in DH5α (Invitrogen, 
Carlsbad, CA)-competent Escherichia coli, and selected colonies 
were cultured. Plasmid DNA was purified using either the 
GenElute Five-Minute Plasmid Miniprep Kit (Sigma) or QIA 
prep MINIprep (Qiagen, Valencia, CA). The DNA sequences and 
reading frames were verified by sequence analysis at the Molecular 
Biotechnology core facility at the Cleveland Clinic using an ABI 
Prism 377 Automated DNA Sequencer (Applied Biosystems, 
Foster City, CA).
Transient Transfection and Generation of Stable Clones
HEK293T cells were cotransfected with each of the plasmid 
constructs pMSCV-3HA-OGRl, pMSCV-3HA-OGRl-EGFP, 
pMCV-EGFP, or pMSCV empty vector and packaging plasmid 
using a calcium phosphate transfection kit (Invitrogen) according 
to the manufacturer’s instructions. The media containing the virus
were collected 3 days after transfection, and the viral particles were 
collected by centrifugation at 1620g for 30 minutes at 4 oC. PC3 cells 
were plated into six-well tissue culture dishes and infected with 
1-2 mL of the virus-containing media from transfected HEK293 
cells. Infected cells were transferred to 10-cm dishes 3 days later. 
Stable single PC3 cell colonies (monoclonal) or pooled cells 
(polyclonal) were selected with puromycin (2.5 μg∕mL). Clones 
expressing OGR1 or vector were designated as OGR1-PC3, 
OGR1-EGFP-PC3, vector-PC3, and EGFP-PC3. For PC3 cell- 
transient transfection, PC3 cells were transfected with 1.0-1.5 μg 
of pcDNA3-OGRl, pcDNA3-GPR4, or pcDNA3-OGRl-H245F 
or were cotransfected with pcDNA3-OGRl and pcDNA3-Gαil 
dominant-negative plasmids in six-well plates using lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol. C4-2 
and DU145 cells were transiently transfected with 1.0-1.5 μg of the 
pcDNA3 empty vector or the pcDNA3-OGRl plasmid. Cellular 
assays were conducted 48-72 hours after transfection.
Human Prostate Cancer Metastasis Orthotopic
Mouse Model
All mouse studies were approved by the Indiana University School 
of Medicine or the Cleveland Clinic Institutional Animal Care and 
Use Committees. In these studies, 5- to 7-week-old male athymic 
(nu∕nu, n = 26) or NOD/SCID (n = 32) mice were anesthetized 
using isoflurane (2%-4%), nembutal (50 mg∕kg), or ketamine 
(200 mg∕kg). An abdominal incision (5-10 mm) was made in each 
mouse, and the prostate gland was exposed and injected once with 
either OGR1-PC3 (n = 7), OGR1-EGFP-PC3 (n = 25), vector-PC3 
(n = 3), or EGFP-PC3 (n = 23) cells (5.0 x 106 cells in 40-50 μL 
phosphate-buffered saline [PBS: sodium chloride, 145 mM {O.85%} 
in phosphate buffer, 150 mM {Sigma}]). After injection, prostate 
glands were placed back into the peritoneal cavity, and the incisions 
were surgically closed.
Postsurgical and Necropsy Procedures
Following tumor cell injection, mice were observed daily for signs of 
tumor development, including hunched posture, abdominal bloat­
ing, or loss of mobility. Alice were killed on day 45 when tumors had 
metastasized to other organs in the control mice by CO2 inhalation, 
and necropsies were performed to assess tumor growth and metas­
tasis. Metastases in different organs were measured and counted 
using fluorescence or light microscopy. All primary prostate tumors 
and metastases were harvested, fixed in 10% neutral buffered forma­
lin, embedded in paraffin, sectioned into 5-μm slices, and then either 
stained with hematoxylin and eosin or immunostained using anti­
bodies as described below. Bones (ribs, tibia, and femur) from mice 
injected with control EGFP-PC3 or OGR1-EGFP-PC3 clones 
were removed, dissected free of most adherent tissues, and observed 
immediately with epifluorescence microscopy. In addition, bones 
were fixed in 4% paraformadehyde and decalcified in 14% EDTA 
(pH 7.4) for 2 weeks at 4 oC. The decalcified bones were sectioned 
and observed using epifluorescence microscopy.
Microscopy and Reverse Transcription-Polymerase 
Chain Reaction to Detect Metastases
Tumors expressing EGFP were observed using a Leica fluorescent 
stereomicroscope equipped with green (fluorescein, 480Ex∕530Em)
and red (TexasRed, 560Ex∕630Em) filters (model MZ 16FA). The 
green and red images were merged, and the metastases in the 
mice that had been injected with OGR1-EGFP-PC3 and EGFP- 
PC3 were compared using Image ProPlus software (Media cyber­
netics, Bethesda, MD). A light stereo microscope (model 
SMZ1000, Nikon, Fryer Co Inc, Huntley, IL) equipped with a 
Nikon digital camera (DXM1200F) was used to analyze tumor 
size and metastases to different organs. For quantification of in 
vitro fluorescence, images were captured from four fields per well 
(three wells per sample) at ×40 magnification using a Nikon epi-
fluorescence microscope. Images were saved in JPEG format and 
converted into Canvas 9 (ACD System, Miami, FL) format for 
analysis. Background fluorescence was approximated from a well 
of control PC3 cells (i.e., that had not been transfected with an 
EGFP-containing vector) and subtracted from the levels of fluo­
rescence from test cells.
To detect potential microscopic tumors, small portions of liver 
(three to four portions per mouse) were collected from seven to 
eight mice from each group of EGFP-PC3 or OGR1-EGFP-PC3. 
Total RNA was isolated, and reverse transcription (RT)-PCR was 
carried out using primers specific for EGFP and β-actin. The 
primers for EGFP were 5'-CCT ACG GCG TGC AGT GCT 
TCA GC-3' (forward) and 5'-CGG CGA GCT GCA CGC TGC 
GTC CTC-3' (reverse). The primers for β-actin were 5'-AAG 
GCC AAC CGT GAA AAG ATG ACC-3' (forward) and 5'-ACC 
GCT CGT TGC CAT TAG TGA TGA-3' (reverse) (GenBank 
accession number NM_OO7393).
In Vivo Primary Tumor Cell Proliferation Assay
Cell proliferation in primary prostate tumors was assessed using 
5-bromo-2-deoxyuridine (BrdU; Sigma) staining. Mice were in­
jected intraperitoneally with 40 mg/kg body weight of BrdU. After 
2 hours, mice were killed as described above, and primary prostate 
tumors were excised, formalin fixed, and embedded in paraffin 
(from each primary tumor of seven to eight mice per group).
Immunohistochemistry for OGR1, 5-Bromo-
2-Deo×yuridine, and Natural Killer Cells
Immunostaining was performed on primary tumor sections using 
the Vectastain Universal ABC kit (Vector Laboratories). Briefly, 
paraffin-embedded tissues were deparaffinized with xylene or 
Histo-Clear (National Diagnostics, Atlanta, GA) and dehydrated 
using decreasing gradient alcohol washes (100%, 95%, and 80% 
ethanol). Antigen retrieval was performed by microwaving the sec­
tions in 10 mM citrate buffer for 1 minute. Sections were then 
blocked with horse serum (included in the Vectastain Universal 
ABC kit) (2.5% in PBS) and incubated overnight with rabbit 
anti-human OGR1 polyconal antibody (1:500 dilution) or for 30 
minutes with rat anti-mouse monoclonal CD49b (NK1.1, 1:250 
dilution) or mouse monoclonal anti-BrdU sera (1: 500). Sections 
were then incubated with biotinylated pan-specific universal 
secondary antibody (according to the user manual from Vector 
Laboratories) for 10 minutes, followed by incubation with 
streptavidin-peroxidase for 5 minutes and 3, 3'-diaminobenzidine. 
The staining levels in the negative controls (duplicate slides 
without primary antibodies) were used as background. All cells 
that stained brown were considered positive. Immunostaining was
scored (×20 magnification) on triplicate tissue sections from 
each group of mice by an independent observer blindly (Dr 
Weiling Xu).
Terminal Transferase dUTP Nick End Labeling Assay to 
Detect Cells Undergoing Apoptosis
Terminal transferase dUTP nick end labeling assays were per­
formed to detect apoptotic cells in the primary tumors by using 
an Apoptag Peroxidase In Situ Apoptosis Detection Kit 
(Chemicon, Temecula, CA). Tumor sections (from seven to eight 
mice per group) were deparaffinzied and rehydrated as mentioned 
above and then incubated in 20 μg∕mL proteinase K for 15 min­
utes at room temperature and washed twice with distilled water. 
Next, the endogenous peroxidase activity in the tumor sections 
was blocked by incubation for 5 minutes with 3 % H2O2 in PBS, 
followed by incubation for 10 seconds with equilibration buffer. 
The sections were then incubated for 1 hour at 37 oC with termi­
nal deoxynucleotidyl transferase enzyme in reaction buffer 
(according to the manufacturer’s instructions). The reaction was 
terminated by incubation with stop buffer at room temperature. 
Sections were then incubated with peroxidase-conjugated anti- 
digoxigenin antibody for 30 minutes, and the reaction was devel­
oped with diaminobenzidine substrate for 4 minutes at room 
temperature.
RNA Isolation and RT-PCR to Measure OGR1 and 
EGFP mRNA Expression
Total RNA was extracted from 5.0 × 105 to 6.0 x 105 OGR1-PC3, 
vector-PC3, DU145, and C4-2 cells or from 2.5 mg of 
primary tumors or livers from mice injected with vector-PC3 and 
OGR1-PC3 clones using the total SV RNA isolation kit (Promega, 
Madison, WI) following the manufacturer’s protocol. First-strand 
cDNA was synthesized from 2.5 μg DNA-free total RNA using 
the SuperScript II first-stand synthesis kit (Invitrogen). OGR1 
expression levels were analyzed by semi-quantitative RT-PCR. 
Glyceraldehyde-3-phosphate dehydrogenase served as the 
loading control. RT-PCR for the OGR1-EGFP fusion protein 
was performed with an OGR1-specific forward primer (5'- 
TCCGGGAAAAGCGGGGC-3') and an EGFP-specific reverse 
primer (5'-TGCAGAAATTCTTACTTGTACAGCTCGTCCA 
TG-3'). For OGR1, RT-PCR was performed using OGR1-specific 
forward (5'-CTGCCTGTCCCTCTACTTCG-3') and reverse 
(5'-TGTTCTCGTACAGGAGGATGC-3') primers. Quantita­
tive PCR was performed with primers obtained from Gorilla 
Genomics, Inc (Alameda, CA). The primer sequences for 
OGR1 were 5'-CACCGTGGTCATCTTCCTG-3' (forward) 
and 5'-GGAGAAGTGGTAGGCGTTGA-3' (reverse). The β2- 
microglobulin housekeeping gene (NM_004048) was used as the 
loading control. The primer sequences used to amplify the β2- 
microglobulin were 5'-ACTGGTCTTTCTATCTCTTGTACT-3' 
(forward) and 5'-CTGCTTACATGTCTCGATCC-3' (reverse). 
Experiments were performed three times in triplicate for each cell 
line. The primers used for measuring EGFP mRNA in the liver 
tissues were 5'-GACGACGGCAACTACAAGA-3' (forward) and 
5'-GATGCCGTTCTTCTGCTT-3' (reverse). PCR was per­
formed with RNA isolated from three to four portions of each liver 
per mouse from 16 mice per group.
Immunoblot for G protein alpha-inhibitory subunit 1
Vector-PC3 and OGR1-PC3 cells (at 80%-85% confluence 
in a six-well plate) were treated with or without actinomycin D 
(500 ng/mL Calbiochem, San Diego, CA) for 24 hours. Total 
protein was extracted and quantified using the BCA Protein Assay 
Kit (Pierce, Rockford, IL). Equal amounts of protein per lane were 
separated on 10% sodium dodecylsulfate minigels and then electro- 
phoretically transferred to Immobilon P polyvinylidene difluoride 
membranes (Millipore, Billerica, MA). Membranes were blocked in 
5% nonfat dry milk in Tris-buffered saline containing 0.2% Tween 
20 (TBST) for 2 hours at room temperature and then incubated 
with rabbit polyclonal anti-Gαil antibody overnight at 4 oC (1:1000 
dilution), washed three times with TBST, incubated with goat 
anti-rabbit IgG horseradish peroxidase-conjugated secondary 
antibody (1:4000 dilution), and finally washed three times with 
TBST. Antibody-protein complexes were visualized using the 
ECL Western Blotting Detection System (Amersham Biosciences, 
Piscataway, NJ). The membranes were then stripped and reblotted 
with monoclonal mouse β-actin antibody (1:3000 dilution) to 
assess protein loading and transfer. Immunoblotting was performed 
three times using vector-PC3, EGFP-PC3, OGR1-PC, and OGR1- 
EGFP-PCs cells.
pH Effect Studies
To test the effect of pH on tire secretion of arachidonic acid (AA) 
and LPC in OGR1-PC3 cells, physiologic salt solutions (PSS; 130 
mM NaCl, 0.9 mM NaH2PO4, 5.4 mM KC1, 0.8 mM MgSO4, 1 mM 
CaCl2, 25 mM glucose, and 20 mM HEPES) at three different 
pHs (6.8, 7.4, and 7.8) were prepared (25). Vector-PC3 and OGR1- 
PC3 cells were incubated with each of the PSS for 90 minutes in a 
humidified 5% CO2 atmosphere chamber at 37 oC. Cell superna­
tants were collected, and AA and LPC were extracted as described 
below. Five independent experiments were performed in triplicate.
Preparation of Conditioned Media
Vector-PC3 and OGR1-PC3 cells were grown in 10-cm2 tissue 
culture plates to 85%-95% confluence. The media was then 
removed, the cells were washed twice with PBS, and serum-free 
RPMI-1640 medium containing 100 units/mL penicillin-strepto­
mycin and 2 mM glutamine (6 mL) was added to each plate. The 
conditioned medium was collected after 12-16 hours of incuba­
tion and stored at -80 oC in glass or siliconized plastic tubes before 
analysis. For experiments using pertussis toxin (PTX) treatment, 
vector-PC3 and/or OGR1-PC3 cells were plated as above and pre-
treated with 100 nM PTX for 16 hours. The PTX media was 
removed, and the cells were washed twice with PBS and incubated 
in either serum-free or complete medium (RPMI-1640 with 10% 
FBS), and medium was collected as described above. This proce­
dure was performed three times in triplicate.
Migration Assay
Parental PC3 cells and PC3 clones were cultured to 85%-95% 
confluence and subjected to serum starvation for 16 hours before 
assay. Cells were dissociated by incubation with trypsin-EDTA 
(0.05% trypsin, 53 mM EDTA), washed twice with PBS, and 
counted using a hemocytometer. The lower side of the insert of the 
24-well transwell migration chamber membrane (8.0 μm pore size;
Corning Inc, New York, NY) was coated with 10 pL of 10 μg∕mL 
vitronectin (Chemicon,) and dried at room temperature. Vitronectin 
was chosen among several ECM proteins tested because it was the 
substrate on which OGR1 had the maximal inhibitory effect on 
cell migration; thus, differences between groups could be readily 
observed. Serum-free media (300 pL) was added to each lower 
chamber of the 24-well transwell. Inserts (the upper chambers) were 
then placed in the wells (the lower chambers). Cells (0.5 × 105 to 
1.0 × 10s in 300 pL serum-free media) were added to each upper 
chamber and incubated for 4.5 hours. Nonmigrating cells were re­
moved with a cotton swab. The cells that migrated to the lower 
phase of the upper chamber were then fixed in methanol for 30 min­
utes and stained with crystal violet (1 g∕mL, Fluka Chemical Corp, 
Milwaukee, WI) for 30 minutes at room temperature. Excess stain 
was removed with water, and the chambers were air-dried. Cells 
were then visualized under the microscope and quantified by count­
ing the number of cells in three randomly chosen fields. At least 10 
independent experiments were performed, each in triplicate.
To study the effect of conditioned media on cell migration, 
parental PC 3 cells were serum starved for 16 hours, treated with 
trypsin-EDTA, washed twice with PBS, counted, and then prein­
cubated with conditioned media (see above) or lipid extracts from 
conditioned media (see below for lipid extraction) for 30 minutes 
on a rotator in a cell culture incubator before being used for 
migration assays. At least eight independent experiments were 
performed, each in triplicate.
Transendothelial Migration Assay
A monolayer of HMEC-1 cells was generated on 24-well transwell 
migration chambers by seeding 5.0 × 106 cells. Control EGFP- 
PC3 or OGR1-EGFP-PC3 cells were added directly on top of the 
endothelial cell layer, as described above. Non-GFP cells were 
treated with calcein AM (10 pmol/mL) (Invitrogen) for 30 min­
utes, washed twice, and then added on top of the endothelial cell 
layer. Migrated cells were fixed with methanol for 20 minutes and 
counted using a fluorescence microscope. Three independent 
experiments were performed, each in triplicate.
In Vitro Cell Proliferation Assay
OGR1-PC3, OGR1-EGFP-PC3, vector-PC3, and EGFP-PC3 
clones were seeded in 48-well plates (5000 cells per well). After 6 
hours, the medium was replaced with RPMI-1640 supplemented with 
or without 2% FBS. Cells were stained with 2% trypan blue and cell 
proliferation at 24, 48, and 72 hours was assessed by counting using a 
hemocytometer or by MTT assay. For the MTT assay, 30 pL of 
MTT (5 mg/mL in PBS) was added to each well containing 200 pL 
media and incubated at 37 oC for 3 hours. After the cell culture 
medium was removed, 200 pL of dimethyl sulfoxide was added to each 
well to solubilize the dye. Absorbance was examined at 570 nm using 
a Victor3 plate reader (PerkinElmer Life and Analytical Sciences, 
Shelton, CT). Three independent experiments were performed 
(using EGFP-PC3 and OGR1-EGFP-PC3 cell hnes) in triplicate.
Heat Treatment, Lipid Extraction From Conditioned 
Media, and Mass Spectrometry Analyses
To study the effect of heat-treated conditioned media on paren­
tal PC3 cell migration, conditioned media from OGR1-PC3,
OGR1-EGFP-PC3, vector-PC3, or EGFP-PC3 cells were 
heated in an immersion circulating water bath (PolyScience, 
Niles, IL) at 95 oC for 30 minutes. The media were centrifuged 
at 13 400g for 10 minutes at 4 oC and used for migration assays. At 
least five independent experiments were performed for each cell 
line, each in triplicate.
LPC was extracted from the conditioned media from vector- 
PC3 or EGFP-PC3 and OGR1-PC3 or OGR1-EGFP-PC3 using 
the method of Bligh and Dyer (26). In brief, 10 μL of 12:0 LPC 
(1 μM) was added (as an internal standard, IS) to 1.8 mL condi­
tioned medium, which was mixed with 3 mL of methanol/chloro- 
form (2 :1). The samples were mixed by vortexing for 1 minute and 
incubated on ice for 10 minutes. Chloroform (1 mL) was added to 
separate the phases, and the samples were mixed by vortexing for 
1 minute and then centrifuged (1750g for 10 minutes, at 4 °C). 
The lower phase was transferred to a new glass tube. The upper 
phase was re-extracted and the lower phases were combined. The 
experiment was performed at least seven times independently, each 
in triplicate. Arachidonic acid was extracted using ethyl acetate 
(27). In brief, 1 mL of conditioned medium from each sample was 
mixed with 3 mL of ethyl acetate, and 10 pL of HC1 was added. 
The samples were vortexed for 1 minute and then centrifuged 
(1750g for 10 minutes, at 4 °C). The upper phase was transferred 
to a new glass tube, the solvent was evaporated under nitrogen 
at room temperature, and the dried lipids were resuspended in 
100 pL of methanol for mass spectrometry (MS) analyses.
MS analyses of lipid extracts from conditioned media samples 
were performed using API-4000 LC-MS-MS (Applied Biosystems∕ 
MDS SCIEX). Data processing was highly automated using the 
mass spectrometer software and Excel. Samples (10 pL) were 
directly delivered into the electrospray ionization source through 
the LC system (Agilent 1100) with an autosampler. The mobile 
phase was methanol/water/AmOH (90:10:0.1, vol/vol/vol) with a 
flow rate of 0.1 mL∕min and 3 minutes for each sample. Quantitative 
analyses were performed using the methods described previously 
(28,29) in the multiple reaction monitoring mode. The peak inten­
sity ratios (standard/IS) versus the concentration ratios (standard/ 
IS) were plotted and fitted using linear regression. At least seven 
independent experiments were performed, each in triplicate.
Statistical Analysis
Data are presented as means with 95% confidence intervals (CIs) 
of at least three independent experiments. Different values among 
groups were compared using Student’s t test. All statistical tests 
were two-sided, and P values less than .05 were considered to be 
statistically significant.
Fig. 1. Ovarian cancer G protein-coupled receptor 1 (OGR1) mRNA 
expression in PC3 clones. PC3 human prostate cancer cells were trans­
fected with one of the following DNA constructs: control retrovirus 
vector-enhanced green fluorescence protein (pMSCV-EGFP), pMSCV 
alone, pMSCV-OGR1-EGFP, or pMSCV-OGR1. Stable clones were 
selected by puromycin treatment (2.5 μg/mL). OGR1 expression in sta­
ble clones was analyzed by reverse transcription-polymerase chain 
reaction. Controls were clones selected from PC3 cells transfected with 
control vectors pMSCV and pMSCV-EGFP. Samples #1 and #2 were 
single stable clones and sample #3 was pooled (mixing several different 
single stable EGFP-positive) OGR1-EGFP-PC3 clones. Samples #4, #5, 
and #6 were OGR1-PC3 clones (without EGFP). The housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the 
loading control. One representative image of three independent experi­
ments is shown.
Results
The Metastatis Suppressive Role of OGR1 In Vivo
Expression of OGR1 has been shown to be fivefold lower in meta­
static tumors than in primary prostate tumors (24), implying that 
OGR1 may have an inhibitory role in tumor metastasis. To inves­
tigate the direct role of OGR1 in tumor metastasis, we established 
several PC3 cell clones that stably overexpress OGR1. PC3 cells 
were chosen because of their high metastatic potential and because 
they have been used successfully in mouse models of metastatic
prostate cancer (30). All the OGR1-PC3 clones used in this report 
expressed 4-fold to 10-fold more OGR1 mRNA than parental PC3 
cells, as assessed by quantitative PCR (data not shown).
Stable clones of PC3 cells that were transfected with vector 
controls (vector-PC3 and EGFP-PC3) expressed very low levels of 
endogenous OGR1 mRNA (Figs. 1 and 2, G). However, cells that 
were transfected with OGR1 expression vectors (OGR1-PC3 or 
OGR1-EGFP-PC3) overexpressed OGR1 (Fig. 1). To avoid dif­
ferential effects resulting from different OGR1 insertion sites 
across clones, both selected single-cell clones and a pooled clone 
(a pool of several selected single-cell clones) of PC3 cells were used 
in subsequent experiments. OGR1 was fused to EGFP to enable 
easy observation and analysis of PC3-derived primary and meta­
static tumors using fluorescence microscopy. However, to avoid 
potential EGFP-related nonspecific effects, we also transfected 
cells with OGR1 plasmids without the EGFP fusion (OGR1-PC3 
clone).
To study the effect of OGR1 on tumoriginesis and metastasis 
in vivo, we used mouse models of metastatic prostate cancer. 
Athymic and NOD/SCID mice were randomly divided into two 
groups (three to eight mice per group), and PC3 clones were 
injected orthotopically into the prostate gland of each mouse. 
Forty-five days later, mice were killed and tumor development was 
examined. Mice that had been injected with vector-PC3 or EGFP- 
PC3 formed primary tumors in the prostate glands and metastatic 
tumors in the liver, spleen, kidney, stomach, lung, lymph nodes, 
diaphragm, and mesentery (Fig. 2, A-C; arrows indicate tumor 
loci). In contrast, the mice that were injected with the OGR1-PC3 
or OGR1-EGFP-PC3 clones developed tumors that were con­
fined to the prostate gland and did not metastasize to any of the 
other organs examined (Fig. 2, A-C). To rule out a potential non-
specific effect of EGFP, we also tested the effect of OGR1-PC3 
(without EGFP fusion) cells in mice, using the vector-PC3 cells as 
the control.
We conducted four independent sets of experiments (Table 1) 
in athymic and NOD/SCID mice. Overall, we observed a statis­
tically significant reduction in metastases when exogenous
Fig. 2 (continues)
Fig. 2. Ovarian cancer G protein-coupled receptor 1 (OGR1) expression 
and PC3 cell metastasis in vivo. PC3 cells (5.0 × 106) from clones 
expressing enhanced green fluorescence protein (EGFP) as a control 
(CONTROL) or clones expressing OGR1-EGFP (OGR1) were injected 
into the prostate lobes of 5- to 8 week-old athymic or NOD/SCID mice. 
A and B) On day 45 after injection, athymic mice (A) or SCID mice (B) 
were analyzed for metastasis to different organs or anatomic regions. 
Examination of tumor development in different organs was performed 
by light stereo microscopy (A, a and b and B, i-p) or fluorescence stereo 
microscopy (A, c-p and B, a-f). C) Images of metastatic tumors (a and 
b) and primary prostate tumors (athymic mice, c and b; NOD/SCID 
mice, e and f) are shown. Arrows indicate the tumors derived from PC3 
cells implanted into the prostate. The area surrounded by the dotted 
lines indicates the primary prostate tumor. The size of the primary 
tumor was quantified, and mean (95% confidence intervals) volumes 
are shown in (g). D) EGFP expression in stable clones of control EGFP- 
PC3 and OGR1-EGFP-PC3 in vitro. Equal number of cells were seeded 
in a six-well plate, and images of the cells were captured with an epi-
fluorescence microscope using ×40 magnification (a and b). Mean (and 
95% confidence intervals) fluorescence intensity is shown (c). E) In vivo
primary prostate tumor cell proliferation assays were carried out by 
injecting BrdU (intraperitoneally, 40 mg/kg body weight), which is 
incorporated by proliferating cells (a and b). BrdU-positive cells were 
quantified, and the mean (and 95% confidence interval) number of 
stained cells is shown (c). F) Terminal transferase dUTP nick end label­
ing assay of the primary tumor sections was performed to detect apop- 
totic cells. The brown color stained cells indicate the cells undergoing 
apoptosis (arrow head). Mean (and 95% confidence intervals) numbers 
of apoptotic cells per field are shown (c). G) OGR1 protein expression in 
prostate tumors from mice injected with control (either vector-PC3 or 
EGFP-PC3) or OGR1-PC3 (either OGR1-PC3 or OGR1-EGFP-PC3) cells 
were analyzed by immunohistochemistry with an anti-human OGR1 
antibody. H) Detection of potential miscroscopic metastatic tumors. 
Small portions of the livers without overt tumors from mice injected 
with control and OGR1-PC3 cells were collected, and total RNA was 
isolated. A liver metastatic tumor from a control mouse was used as a 
positive control (Cont). Reverse transcription-polymerase chain reac­
tion was conducted using specific primers for EGFP and β-actin. 
Samples in lanes 1-7 are from tissues without overt tumors. Five inde­
pendent experiments were performed.
OGR1 was expressed in PC3 cells as compared with control cells. 
Metastatic foci were not found in any organ (other than the pros­
tate) in 28 out of 32 mice in OGR1 groups (OGR1-EGFP-PC3 
and OGR1-PC3 as single-cell clones or a pooled clone) (Table 
1). The remaining four mice in this group developed several 
small tumors (mean = 12.50%, 95% CI = 4.08% to 29.93%) that 
were localized to the mesentery (<2mm in size) (Table 1). In 
contrast, all 26 control mice (mean = 100%, 95% CI = 83.97% 
to 100%) injected with vector- or EGFP-PC3 cells had numer­
ous metastatic foci in multiple organs (Table 1). In addition, 
the metastases in control mice were larger (>2 mm) and often 
fused together to form tumor aggregates (Fig. 2, A and Table 
1). We did not observe bone metastases in either the control or 
the OGR1 mice (data not shown), which is consistent with pre­
vious reports using the same PC3 injection model (31,32). In 
addition, we tested the potential existence of microscopic 
tumors using PCR-based detection of EGFP in the liver samples 
collected from both control (EGFP-PC3) and OGR1 (OGR1- 
EGFP-PC3) groups. Although EGFP was detected in overt 
tumors, no EGFP was detected in liver samples that appeared to 
be tumor free, suggesting the absence of microscopic tumors 
(Fig. 2, H).
We obtained similar results in athymic mice and NOD/SCID 
mice (Fig. 2, B and Table 1), which do not have normal T and B 
cells, suggesting that both T and B cells do not play an important 
role in OGRl’s metastatis suppression effect. In addition, we per­
formed immunohistochemistry using the CD49b (NK1.1) anti­
body and found no difference in the number of natural killer (NK) 
cells in tumor sections derived from control cells and OGR1- 
expressing cells (data not shown), suggesting that NK cells may 
also do not play an important role in OGRl’s metastasis suppres­
sion effect.
We next compared growth of primary tumors in mice that were 
injected with either vector control or OGR1-PC3 cells. These 
mice developed primary prostate tumors that were similar in size, 
suggesting that OGR1 did not affect primary tumor growth 
(Fig. 2, A, o and p; Fig. 2, B, e-h; Fig. 2, C, c-f; Table 1). 
The fluorescence intensity of the primary tumors in the OGR1 
mice appeared lower than that of the control mice (compare 
Fig. 2, A, o and p and Fig. 2, B, e and f). This difference was mainly 
due to lower EGFP expression in the OGR1-EGFP-PC3 cells 
compared with that in EGFP-PC3 cells (Fig. 2, B and D).
To further evaluate the effect of OGR1 overexpression on pri­
mary tumor cell proliferation, we conducted BrdU incorporation 
and terminal transferase dUTP nick-end labeling assays in xeno­
graft tumors from the athymic or the NOD/SCID mice. We 
observed that primary prostate tumors derived from vector control 
and OGR1-PC3 cells had similar BrdU incorporation (Fig. 2, E). 
Minimal apoptosis was detected in tumor sections derived from 
both control and OGR1-expressing cells (Fig. 2, F), confirming 
that OGR1 did not affect growth and apoptosis of the primary 
tumors.
Thus, by the definition of metastasis suppressor gene (3,7), our 
data support the hypothesis that OGR1 is a novel metastasis sup­
pressor gene in prostate cancer. We also confirmed that tumors 
derived from OGR1-PC3 cells still expressed OGR1 as assessed by 
immunohistochemical staining (Fig. 2, G).
Table 1. Summary of analysis for metastasis and primary tumor 
size in prostate cancer orthotopic mouse model using athymic 
and SCID mice*
Characteristic Control (N = 26) OGR1 (N = 32) Pt
Mice with
metastases
Number 26 of 26 4 of 32 <.001
Percent 100 (83.97 to 100) 12.50 (4.08 to 29.9)
(95% Cl) 
Percent
reduction
Metastases
per mouse 
≤2 mm, mean 101.4 (91.8 to 111.0)
87.5
.56 (0.40 to 0.72) <.001
(95% Cl)
>2 mm, mean 114.5 (107.9 to 121.0) 0 (0.0 to 0.0) <.001
(95% Cl)
Primary tumor 
size, cm3
Mean (95% Cl) 5.25 (5.07 to 5.42) 5.20 (4.99 to 5.41)
* Metastases were found in the liver, mesentery, intestine, stomach, spleen, 
lymph node, kidney, diaphragm, and lung. In the control group, 16 SCID and 
seven athymic mice were injected with EGFP-PC3 cells; three athymic mice 
were injected vector-PC3 cells. In the OGR1 group, 16 SCID and five athymic 
mice were injected with single clones of OGR1-EGFP-PC3 cells, four athymic 
mice were injected with pooled clones of OGR1-EGFP-PC3 cells, and seven 
athymic mice were injected with OGR1-PC3 cells. SCID = severe combined 
immunodeficiency; OGR1 = ovarian cancer G protein-coupled receptor 1;
Cl = confidence interval; EGFP = enhanced green fluorescence protein.
t P values (two-sided) were calculated using Student's t test.
The Effect of OGR1 on Cell Migration and the
Involvement of Gαi Protein in the Inhibitory Effect
To determine the molecular mechanisms by which OGR1 suppresses 
tumor metastasis, we examined the effect of OGR1 on cell migration 
in vitro. We tested PC3 cell migration to several extracellular matrix 
(ECM) proteins (fibronectin, laminin, vitronectin, collagen I, and 
collagen IV) using transwell assays. OGR1 expression, either with or 
without fusion to EGFP, statistically significantly inhibited cell 
migration to vitronectin reduction compared with the controls 
(mean percentage of cells migrated, 30.2% versus 100%, difference = 
69.8%,95% CI = 63.0% to 75.9%;P<.OOl; Fig. 3, A and C (CONT; 
data from both vector-PC3 and EGFP-PC3 were taken as 100%. 
OGR1#1 = OGR1-PC3 and OGR1#2 = EGFP-OGR1-PC3). Other 
ECM proteins either induced low levels of haptotaxis of the parental 
cells, and OGR1 expression did not induce as much of an effect with 
the other ECM proteins as it did with vitronectin (data not shown). 
Thus, vitronectin was chosen as the ECM for the remainder of the 
migration assays. In contrast to OGR1, expression of GPR4, the G 
protein-coupled receptor sharing the highest homology with OGR1, 
did not affect PC3 cell migration to vitronectin, suggesting a specific 
function of OGR1 (Fig. 3, A and B). We also conducted transendothelial 
 migration assays to mimic the intravasation process in vivo 
and found that OGR1 also inhibited this activity to a similar extent 
(70% inhibition) (Fig. 3, C). In addition, we performed cell migra­
tion assays with C4-2 and DU145 prostate cancer cell lines (which 
do not express endogenous OGR1, as assessed by PCR; data not 
shown) and found that OGR1 statistically significantly inhibited 
migration in both cell types similar to that of PC3 cells (70% reduc­
tion in migration, P<.001 for both C2-4 and DU145) (Fig. 4, A),
suggesting that OGR1 s inhibitory effect on cell migration is not 
limited to PC3 cells.
Fig. 3. The effect of ovarian cancer G protein- 
coupled receptor 1 (OGR1) in cell migration to 
vitronectin and the involvement of G protein 
alpha-inhibitory subunit 1. Migratory properties of 
vector- and OGR1-PC3 cells to vitronectin were 
assessed using transwell assays. Stably trans­
fected vector control-PC3 or OGR1-PC3 cells were 
serum starved for 16 hours. Cells (1 × 105) in 300 μL 
of serum-free RPMI were added to the upper 
chamber of a vitronectin-coated transwell, and 
300 μL of serum-free RPMI was added in the lower 
chamber. A) Cell migration of control (CONT, vec- 
tor-PC3 or EGFP-PC3) and two stable clones of 
OGR1-PC3 cells (OGR1#1;OGR1-PC3, and OGR1#2; 
OGR1-EGFP-PC3) and GPR4-PC3 (GPR4) are 
shown. To compare effects of OGR1 and GPR4, 
cells were transiently transfected with OGR1 and 
GPR4 expression vectors or empty pcDNA3 vector 
as control and serum starved, and migration 
assays were conducted 48 hours after transfec­
tion. B and C) Cell migration [transwell (B) and 
transendothelial (C)] in OGR1-PC3 cells compared 
with parental or vector-PC3 cells (***P<.001). 
Rvalues were calculated using two-sided Student's 
t test). More than 10 independent experiments 
were performed in triplicate.
Fig. 4. The effect of ovarian cancer G protein-coupled receptor 1 (OGR1) 
on cell migration toward vitronectin in two other prostate cancer cell 
lines, C2-4 and DU145. A) C2-4 (solid bars) and DU145 (open bars) cells 
were transiently transfected with empty vector or a OGR1 plasmid and 
subjected to migration assay as in Fig. 3. B) Effects of treatment with 
pertussis toxin (PTX) (100 ng∕mL) for 16 hours or transfection (1.5 μg of 
DNA per six-well plate) with a dominant-negative (DN-) form of 
G protein alpha-inhibitory subunit 1 (Gαi1) on the inhibition of OGR1- 
PC3 cells migration. In A and B, mean (and 95% confidence intervals)
percentages of migrated cells (result from four independent experi­
ments in triplicate) are shown. P values (two-sided) were calculated 
using Student's t test. C) lmmunoblotting was performed to test the 
effect of OGR1 on the expression of Gαi1 protein level in two pairs of 
the control and the OGR1 cell lines in the absence (pair #1; vector-PC3 
and OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3) or in the pres­
ence of actinomycin D (pair#2 + ActD). The membrane was reprobed 
for β-actin to check for equal loading. One representative blot from 
three independent experiments is shown.
To explore the mechanism of this inhibition, we tested the effect 
of PTX on the cell migration of vector- and OGR1-PC3 cells. 
PTX pretreatment stimulated cell migration of OGR1-PC3 cells 
but had no effect on vector-PC3 cells, suggesting that activating 
Gαi proteins, which are sensitive to PTX, are involved in OGR1- 
induced inhibition of cell migration. To confirm this result, cells 
were transfected with a dominant-negative form of Gαil and cell 
migration was monitored as before. The dominant-negative form 
of Gαil reversed the effect of OGR1 (Fig. 4, B), similar to that seen 
with PTX, confirming the involvement of a Gαil protein in 
OGR1's inhibitory effect. Because migration is a critical step in 
tumor metastasis, the reduced cell migration in vitro may be
related to the reduced tumor metastasis that was observed in vivo. 
To explore how OGR1 regulates Gαil, we tested whether OGR1 
expression alters Gαil protein expression. In two pairs of control 
and OGR1-overexpressing cell lines (pair #1; vector-PC3 and 
OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3), OGR1 
expression increased the expression of Gαil protein, which was 
blocked by actinomycin D treatment, suggesting that the regula­
tion was at the transcriptional level (Fig. 4, C).
To determine whether OGR1 affects cell proliferation in vitro, 
we conducted cell proliferation assays (both cell number count and 
MTT assays) in the presence (2% FBS) or absence of growth 
stimulation (0% FBS). Cells from different clones (vector-PC3 and 
OGR1-PC3) were incubated in serum-free media, and cell prolif­
eration was determined after 24, 48, and 72 hours. Similar to what
was observed in vivo, OGR1 expression did not affect cell prolifer­
ation (Fig. 5). These results suggest that the in vitro behavior of the 
cells may reflect, at least in part, their in vivo properties and, thus, 
that some of their signaling mechanisms can be studied in vitro.
Fig. 5. Effects of ovarian cancer G protein-coupled 
receptor 1 (OGR1) expression on prostate cancer 
cell proliferation. In vitro cell proliferation assays 
were carried out in 48-well plates. Vector- or 
OGR1-PC3 cells (5 × 103) were cultured in RPMI 
with or without 2% fetal bovine serum. Cell prolif­
eration was assessed by counting the cells (A 
and B) or by methylthiazolyldiphenyl-tetrazolium 
assays (C and D) at each time point. Mean (and 
95% confidence intervals) numbers of cells 
counted by hemocytometer or absorbance inten­
sity at 570 nm for one representative experiment 
performed in triplicate of more than ten indepen­
dent experiments with similar results are shown.
Fig. 6. Effects on the secretion of an antimigratory lipid factor in a 
G protein alpha-inhibitory subunit-dependent manner by ovarian 
cancer G protein-coupled receptor 1 (OGR1). A) Parental PC3 cells 
were incubated for 16 hours in serum-free RPMI medium, treated 
with trypsin-EDTA, washed twice with phosphate-buffered saline 
(PBS), and replated in conditioned media (CM) collected from either 
vector-PC3 or OGR1-PC3 cells for 30 minutes at 37 °C. Controls were 
treated as above but only washed twice with PBS after 30-minute 
incubation (CM removed). To test the effect of heated conditioned 
media on migration (CM heated), media from either vector-PC3 or 
OGR1-PC3 cells was preheated at 95 °C for 30 minutes and then 
incubated with parental PC3 cell before the cells were subjected to 
the migration assay. Mean (and 95% confidence intervals) percent­
age of cells migrated are shown for one representative of four inde­
pendent experiments performed in triplicate (n = 3). B) The effect of 
lipid extracts prepared from serum-starved (RPMI) and vector-PC3 
(CONT) or OGR1-PC3 (OGR1) cells on cell migration. Mean (and con­
fidence intervals) percentage of cells migrated are shown for one 
representative of four independent experiments (performed in tripli­
cate). C) Vector-PC3 (closed bars) and OGR1-PC3 (open bars) cells 
were either untreated (CONT) or pretreated with 100 ng/mL of per­
tussis toxin (PTX) for 12 hours. Cells were washed twice with PBS 
and incubated in serum-free RPMI for 12 hours. The conditioned 
media was then collected from PTX-pretreated cells and used to 
access its effect on parental PC3 cells migration. Mean (and 95% 
confidence intervals) percentage of cells migrated are shown for one 
representative of four independent experiments performed in tripli­
cate. P values (two-sided) were calculated using Student's t test.
Secretion of an Antimigratory Factor Induced by 0GR1
To test whether OGR1's inhibitory effect on cell migration is 
mediated by the secretion of a soluble factor, conditioned media 
was collected front vector-PC3 and OGR1-PC3 cells. Parental 
PC3 cells were then treated with this conditioned media and 
subjected to cell migration assays. Conditioned media from the
OGR1-PC3 cells, but not vector-PC3 cells, inhibited the migra­
tion (mean percentage of cells migrated, 36.1% versus 100%, dif­
ference = 63.9%, 95% CI = 60.8% to 67.1%; P<.001) of parental 
PC3 cells (Fig. 6, A). The extent of this inhibition (60%-65%) is 
similar to that measured in the OGR1-PC3 cell migration assays 
(~70%). Collectively, these results suggest that a soluble factor(s) 
secreted into the conditioned media derived from OGR1-PC3 cells 
is responsible for the majority of the inhibitory effect on tumor cell 
migration (Fig. 3). To determine whether the conditioned media 
was required during cell migration or whether a short incubation 
time was sufficient for successful suppression, the parental cells
were pre-incubated in conditioned media for 30 minutes. The 
conditioned media was then removed by centrifugation, and the 
cells were resuspended in serum-free media before cell migration 
assays were performed. The inhibitory effect of the conditioned 
media was lost when the conditioned media was removed before 
the cell migration assay (Fig. 6, A), suggesting that a longer prein­
cubation time or the presence of the inhibitory factor during the 
cell migration is necessary.
As the first step to identify the nature of this soluble factor, the 
conditioned media from OGR1-PC3 cells was heated to 95 oC for 
30 minutes before migration assays were performed using paren­
tal PC3 cells. After heating, the conditioned media retained its 
antimigratory activity (Fig. 6, A), suggesting that a lipid factor is 
involved. However, because not all protein/peptide factors are heat 
labile, we cannot rule out the possible involvement of a heat-stable 
peptide factor in this process. To further investigate the nature of 
the factor, organic solvent extracts were prepared from condi­
tioned media collected from OGR1-PC3, parental PC3, vector- 
PC3 cells, and serum-free media using chloroform/methanol 
extraction (2 :1 vol/vol) and tested in migration assays as previously 
described. Parental PC3 cells that were pretreated with solvent 
extracts from OGRl-PC3-conditioned media migrated statisti­
cally significantly less (mean percentage of cells migrated = 25.0%, 
95% CI = 22.7% to 27.3%, P<.001) than cells treated with solvent 
extracts from either the conditioned media from vector-PC3 
(110%, 95% CI = 106.6% to 113.4%) or the serum-free media 
(100%, 95% CI = 63.8% to 136.2%). These results strongly sug­
gest that the factor secreted in conditioned media derived from 
OGR1-PC3 cells is hydrophobic in nature.
To determine whether Gαi protein activation is involved in 
OGRl-induced secretion of this inhibitory factor, OGR1-PC3 
cells were pretreated with PTX before conditioned media was col­
lected. The effect of PTX-treated conditioned media from vector-
and OGR1-PC3 cells on cell migration of parental PC3 cells was 
then compared. Although PTX did not affect migration induced 
by the conditioned media from the vector control cells, it reversed 
the inhibitory effect of the conditioned medium from OGR1-PC3 
cells on cell migration (control versus OGR1: mean percentage of 
cells migrated, 98.7% versus 36.1%, difference = 62.6%, 95% CI = 
50.61% to 74.57%; P<.001; Fig. 6, C), suggesting that Gαi pro­
tein activity is necessary for secretion of the inhibitory factor.
Because control cells (vector-PC3 or EGFP-PC3) did not 
secrete a stimulatory factor in their conditioned media (Fig. 6, B), it 
is likely that OGR1 expression enhances secretion of an inhibitory 
factor(s) instead of inhibiting secretion of a stimulatory factor. Thus, 
we expected to observe an increased amount of a hydrophobic factor 
in conditioned media from OGR1-PC3 cells compared with condi­
tioned media from control cells. AA and LPC are the two major 
products of phospholipase A, (PLA2) enzymes, and some of LPC’s 
biologic activities may be mediated by the OGR1 subfamily of G 
protein-coupled receptors (14,33,34). However, we found that 
OGR1 expression did not increase secretion of either AA or LPC 
into the media at physiologic pH (7.4) (Fig. 7, C and D). Therefore, 
AA and LPC are unlikely to be involved in the inhibitory effect on 
migration. We also compared other positively or negatively charged 
ions in the range of 100-1000 kDa from the solvent extracts from 
the conditioned media from the control versus OGR1 samples using 
MS (data not shown). No molecular species were consistently 
increased in the lipids extracts from OGR1-PC3 cells.
Fig. 7. The effect of sphingosylphosphorylcholine 
(SPC) and proton-sensing function of ovarian 
cancer G protein-coupled receptor 1 (OGR1) on 
cell A) Control- or OGR1-PC3 cells were incu­
bated in serum-free RPMI for 12 hours and then 
untreated (-) or treated (+) with SPC (1 μM) for 30 
minutes. Migration assays were then performed 
as described in Materials and Methods. B) PC3 
cells were transiently transfected with 1.0-1.5 μg 
control vector (CONT), wild-type OGR1 (OGR1- 
WT), or proton-sensing OGR1 mutant DNA 
(OGR1-H245F). Cells were then incubated for 24 
hours and then serum starved for an additional 
12 hours before migration assays were per­
formed. In A and B, mean (and 95% confidence 
intervals) percentage of cells migrated are shown 
for one representative of four independent exper­
iments (performed in triplicate). C and D) Control- 
or OGR1-PC3 cells were incubated in physiologic 
salt solutions of different pHs for 90 minutes. 
Arachidonic acid (AA, C) and lysophosphatidyl- 
choline (LPC, D) were extracted from the cell 
supernatants and quantified. Mean (and 95% 
confidence intervals) concentrations of AA ad 
LPC are shown for one representative of five 
independent experiments performed in triplicate. 
None of the comparisons between control versus 
OGR1 in Figs C and D were statistically signifi­
cantly different (P values were all >.3, as deter­
mined using a [two-sided] Student's t test).
Effects of SPC or OGR1's Proton-Sensing Activities on 
the OGR1 Antimigratory Phenotype
We and others have observed that OGR1 has constitutive activity 
(15,35,36). The in vivo and in vitro effects of OGR1 presented 
above were measured in the absence of exogenous stimuli (other 
than ECM proteins) and with a constant extracellular pH. Therefore,
the activities measured are likely to be mediated through the con­
stitutive activation of OGR1.
To determine whether SPC influences the inhibitory effect of 
OGR1 on cell migration, we treated vector- and OGR1-PC3 cells 
with SPC (1 μM). SPC itself had an inhibitory effect on cell 
migration (Fig. 7, A) that was not affected by OGR1 expression. 
OGR1 has also been shown to have proton-sensing activity dur­
ing inositol phosphate formation in the human embryonic kidney 
HEK293 and other cell types (20,25). In our experiments, the pH 
of the media was not changed, and therefore, it was unlikely that 
the proton-sensing activity of OGR1 is involved in OGRl’s effect 
on cell migration. To further address this issue, we constructed an 
OGR1 mutant (OGR1-H245F) that has impaired proton-sensing 
ability (25). OGR1 H245F showed a similar inhibitory effect on 
cell migration as wild-type OGR1 (Fig. 7, B). Furthermore, we 
tested the effect of pH on AA and LPC secretion related to 
OGR1 expression and found that OGR1 expression did not affect 
AA and LPC production or secretion at any of the pHs tested 
(Fig. 7, C).
Discussion
Metastasis suppressor genes are a class of genes that reduce the 
metastatic propensity of cancer cell lines in vivo without affecting 
their tumorigenesis (2-4). In this article, we presented the follow­
ing evidence to support the hypothesis that OGR1 is a novel 
metastasis suppressor gene in prostate cancer: 1) when OGR1 was 
overexpressed in PC 3 cells, it suppressed tumor cell metastasis in an 
orthotopic mouse model of prostate cancer; 2) OGR1 did not affect 
primary tumor growth, as assessed by the size of the primary 
tumors and by BrdU incorporation assays; and 3) in vitro, OGR1 
expression reduced cell migration, an important step in metastasis, 
without affecting cell proliferation. These data, together with a 
previous report showing that OGR1 expression is reduced in meta­
static compared with primary prostatic tumors (24), support the 
hypothesis that OGR1 may have an important role in the metastasis 
of prostate cancer cells.
OGR1 has been shown to suppress tumor cell growth in ovar­
ian cancer cells (36,37). When OGR1 was expressed fourfold 
to 10-fold above basal levels in PC3 cells, it did not affect cell 
growth. GPR4, a G protein-coupled receptor sharing more than 
50% homology with OGR1, did not inhibit cell migration, sug­
gesting a specific antimigratory role for OGR1. These results 
are consistent with an earlier report showing that GPR4 is 
oncogenic (38).
OGR1 has been shown to have a proton-sensing activity (17,25) 
that may be cell-type and signaling pathway specific (15,25). 
Because an acidic extracellular pH—a characteristic of the micro-
environment of solid tumors—has been shown to enhance tumor 
metastatic potential (39), we have addressed the potential role of 
the proton-sensing ability of OGR1 in our assays. An OGR1 
mutant (H245F) with minimal proton-sensing activity in inositol 
phosphate accumulation had the same effect as wild-type OGR1 
on PC3 cell migration. Furthermore, OGR1 does not affect AA or 
LPC secretion at different pHs as compared with the control. In 
addition, OGRl’s proton sensing activity is mediated by a Gαq 
protein (40). We have observed that a dominant-negative Gαq had
no effect on OGRl’s effect on cell migration (data not shown) and 
Gαil mediates the OGRl’s effect.
OGR1 and related G protein-coupled receptors may have 
dual functions for mediating signals from either lipids or protons 
(19,20,41). SPC, a bioactive lipid molecule, is able to modulate the 
proton-sensing activity of OGR1. In Chinese hamster ovary cells, 
SPC inhibits the acid-induced actions in a pH-dependent manner 
(42). We tested the effect of SPC on migration of PC3 cells and 
found that it was inhibitory. However, this inhibitory effect 
appeared to be independent of OGR1 expression. We cannot com­
pletely rule out that SPC may have an effect in vivo. These issues 
warrant further studies. Together, our data suggest that the 
in vitro effects of OGR1 described in this article are unlikely to 
be related to SPC or proton sensing and are constitutive in nature.
The mechanisms of OGRl’s inhibitory effect on cell migration 
appeared to be related to Gαil protein activation. G protein- 
coupled receptor constitutive activity can induce G protein 
activation. Interestingly, prostate cancer cells express relatively low 
levels of Gαi proteins, which may have an important regulatory 
role in cell proliferation and neoplastic transformation in these 
cells (43). In addition, immunoblot analysis shows that although 
the levels of β subunits of G proteins are maintained, those of αs 
and αi subunits are decreased 30%-40% after neoplastic transfor­
mation (43). We showed here that OGR1 expression increased 
Gαil expression in PC3 cells and that this increase was likely to be 
at the transcriptional level.
Gi protein activation is involved in the stimulation of cell 
migration and in intracellular signaling through receptors for 
lysophosphatidic acid and sphingosine-1-phosphate (44—47). In 
contrast, Gi protein-mediated inhibition of cell migration is much 
less explored. Nevertheless, it has been shown that a Gi-mediated 
inhibition of cAMP accumulation is involved in the inhibitory 
effect of angiopeptin on the migration of vascular smooth muscle 
cells (48).
The present study has several limitations. Only one prostate 
cancer cell line was used in the in vivo models. OGRl’s function 
in additional prostate cell lines should be tested in vivo. Bone 
metastasis is a major issue for human prostate cancer. The role of 
OGR1 in bone metastasis has not been assessed because we did 
not observe bone metastases in either the control or the OGR1 
mice. This issue should be tested in different prostate cancer 
models. In addition, we have not identified the soluble factor that 
is responsible for the inhibitory effect of OGR1 on cell migration. 
It is possible that the migration inhibitory factor is present at 
lower concentrations and thus difficult to detect. It is also possible 
that the size or charge of the molecule is outside the detection 
range that we chose. Further studies are required to identify this 
factor. Nevertheless, our results do suggest that Gi protein activa­
tion is involved in the secretion of this OGR1-induced inhibitory 
factor.
Our results show that OGR1 suppresses prostate cancer metas­
tasis without affecting primary tumor progression, suggesting that 
OGR1 is a novel metastasis suppressor gene for prostate cancer. 
Activation of Gil and the secretion of a hydrophobic factor appear 
to be important for OGRl’s antimetastatic action. Further investi­
gation needs to be conducted to identify the soluble factor(s) 
involved in this process.
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